NTS04f

NTS04f is an investigational ophthalmic antibiotic formulation developed by NTC (NTC Pharma) for the treatment of severe ocular infections, specifically bacterial corneal ulcers and blepharitis. It is a key component of NTC's "Antibiotic Rationalization" program, which aims to provide potent therapeutic alternatives to fluoroquinolones to help mitigate the rise of antibiotic resistance. The drug is likely a formulation of netilmicin, a broad-spectrum aminoglycoside antibiotic that works by inhibiting bacterial protein synthesis. NTS04f has progressed into late-stage clinical development, including a Phase 3 trial (NTC-CU-01) evaluating its efficacy and safety in patients with bacterial corneal ulcers, a condition that requires rapid and effective treatment to prevent permanent vision loss.